Capricor Therapeutics, Inc. (CAPR) — Earnings Call X-Ray
Our AI read all 36 of CAPR's earnings calls (2016–2025) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.
Previous Call Grade
C
Q3 2024
Calls Analyzed
36
2016–2025
Avg Candor
6/9
evasion 3.3/9
Call-by-call analysis
🔒 Q4 2024 earnings call
2025-03-19
NEWEST
Guidance: ■■■■■Demand: ■■■■■■
Margins: ■■■■Backlog: ■■■■
■ analysts, ■■ questionsexpected move ±■■%
Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.
🔒 The Q4 2024 call grade is ready
The full 37-point AI read of CAPR's newest earnings call — grade, expected move, and every question answered — is free with an account.
Sign up free to unlock
C
Q3 2024 earnings call
2024-11-13
move ±19.9%
Management gave no formal guidance against contracting margins. The delivery was rich in specifics, relaxed under questioning, promotional in tone.
Margins: contractingPricing: stableHeadcount: growingCapex: increasing 4 analysts · 10 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead⚑ Reads rehearsed
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
D
Q2 2024 earnings call
2024-08-08
move ±13.4%
Management gave no formal guidance against contracting margins. The delivery was relaxed under questioning, promotional in tone.
Margins: contracting 4 analysts · 10 questions
⚑ Critic ammunition⚑ Question left hanging✓ Resolves doubts⚑ Reads rehearsedFounder-ledDirection beats results
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
D
Q1 2024 earnings call
2024-05-14
move ±12%
Management held guidance steady against accelerating demand. The delivery was rich in specifics, promotional in tone.
Guidance: maintainedDemand: acceleratingPricing: raisingHeadcount: growingCapex: increasing 4 analysts · 8 questions
⚑ Critic ammunition⚑ Question left hanging✓ Resolves doubts✓ Volume step-up ahead⚑ Reads rehearsedFounder-led
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
C
Q4 2023 earnings call
2024-02-29
move ±17.2%
Management held guidance steady against accelerating demand. The delivery was rich in specifics, promotional in tone.
Guidance: maintainedDemand: acceleratingHeadcount: growingCapex: flat 3 analysts · 8 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubts✓ Prepayments growing⚑ Reads rehearsed
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
YES Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
C
Q3 2023 earnings call
2023-11-14
move ±13.5%
Management raised guidance against accelerating demand and contracting margins.
Guidance: raisedDemand: acceleratingMargins: contractingHeadcount: growingCapex: increasing 2 analysts · 7 questions
⚑ Critic ammunition⚑ Question left hanging✓ Resolves doubts✓ Prepayments growing✓ Volume step-up aheadFounder-led
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
YES Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?
D
Q2 2023 earnings call
2023-08-07
move ±27.1%
Management gave no formal guidance against contracting margins. The delivery was rich in specifics, promotional in tone.
Margins: contractingHeadcount: growingCapex: increasing 2 analysts · 7 questions
⚑ Critic ammunition⚑ Question left hanging✓ Resolves doubts⚑ Reads rehearsedFounder-ledDirection beats results
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
F
Q1 2023 earnings call
2023-05-11
move ±9.4%
Management gave no formal guidance. The delivery was rich in specifics, promotional in tone.
2 analysts · 6 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsedFounder-led
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
Earlier calls
| Call | Date | Grade | Guidance | Demand | Margins | Candor | Evasion |
|---|
| Q4 2022 |
2023-03-15 |
D |
maintained | accelerating | contracting |
6/9 |
3/9 |
| Q3 2022 |
2022-11-10 |
C |
maintained | accelerating | unclear |
6/9 |
4/9 |
| Q2 2022 |
2022-08-10 |
D |
none | unclear | contracting |
6/9 |
3/9 |
| Q1 2022 |
2022-05-10 |
D |
none | unclear | contracting |
6/9 |
2/9 |
| Q4 2021 |
2022-03-10 |
C |
none | unclear | contracting |
6/9 |
2/9 |
| Q3 2021 |
2021-11-09 |
D |
none | unclear | contracting |
6/9 |
5/9 |
| Q2 2021 |
2021-08-12 |
D |
none | unclear | unclear |
6/9 |
3/9 |
| Q1 2021 |
2021-05-13 |
D |
none | unclear | contracting |
6/9 |
5/9 |
| Q4 2020 |
2021-03-11 |
D |
maintained | unclear | unclear |
6/9 |
2/9 |
| Q3 2020 |
2020-11-12 |
F |
none | unclear | contracting |
6/9 |
3/9 |
| Q2 2020 |
2020-08-09 |
F |
none | unclear | contracting |
6/9 |
3/9 |
| Q1 2020 |
2020-05-18 |
D |
none | unclear | unclear |
6/9 |
2/9 |
| Q4 2019 |
2020-03-18 |
D |
maintained | unclear | unclear |
6/9 |
3/9 |
| Q3 2019 |
2019-11-08 |
F |
none | unclear | contracting |
6/9 |
5/9 |
| Q2 2019 |
2019-08-06 |
D |
maintained | unclear | unclear |
7/9 |
3/9 |
| Q1 2019 |
2019-05-13 |
F |
none | unclear | unclear |
6/9 |
5/9 |
| Q4 2018 |
2019-03-28 |
F |
none | unclear | unclear |
7/9 |
4/9 |
| Q2 2018 |
2018-11-13 |
F |
none | unclear | contracting |
5/9 |
2/9 |
| Q2 2018 |
2018-08-09 |
D |
none | unclear | unclear |
6/9 |
3/9 |
| Q1 2018 |
2018-05-10 |
D |
maintained | unclear | unclear |
6/9 |
4/9 |
| Q4 2017 |
2018-03-14 |
D |
maintained | unclear | contracting |
5/9 |
2/9 |
| Q3 2017 |
2017-11-08 |
D |
none | unclear | unclear |
5/9 |
3/9 |
| Q2 2017 |
2017-08-11 |
D |
none | unclear | unclear |
8/9 |
2/9 |
| Q4 2016 |
2017-03-15 |
D |
none | unclear | contracting |
5/9 |
4/9 |
| Q3 2016 |
2016-11-10 |
D |
none | unclear | unclear |
6/9 |
5/9 |
| Q2 2016 |
2016-08-15 |
C |
none | unclear | unclear |
7/9 |
3/9 |
| Q1 2016 |
2016-05-13 |
D |
none | unclear | unclear |
6/9 |
3/9 |
| Q4 2015 |
2016-03-17 |
C |
none | accelerating | unclear |
6/9 |
3/9 |
Research question bank — earlier calls
During our 1,600-question research program, batches of experimental hypotheses were tested directly against some of CAPR's earlier calls. The YES answers — the rare hits — are shown; click any question to see every company that matched it. Full list: the question bank.
C
Q2 2016 earnings call
2016-08-15
2 more research questions answered NO
How to read this page
The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.
Companies with similar call quality
← CAPMF All “C” companies
CAR →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our
methodology.